The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ejection fraction (HFrEF) has more than halved the risk of sudden cardiac death (SCD) in this setting. However, SCD remains one of the major causes of death in this patient population. Beyond the acknowledged role of beta blockers and inhibitors of the renin-angiotensin-aldosterone system (RAAS), a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNI), proved to reduce the overall cardiovascular mortality and, more specifically, the risk of SCD in HFrEF patients. The mechanism by which ARNI may reduce the mortality connected with harmful ventricular arrhythmias is not utterly clear. A variety of direct and indirect mechanisms have been suggested, but a favorable left ventricular reverse remodeling seems to play a key role in this setting. Furthermore, the well-known protective effect of implantable cardioverter-defibrillator (ICD) has been debated in HFrEF patients with non-ischemic cardiomyopathy (NICM) arguing against the role of primary prevention ICD in this setting, particularly when ARNI therapy is considered. The purpose of this review was to provide insights into the SCD mechanisms involved in HFrEF patients together with the current role of electrical therapies and new drug agents in this setting. [Figure not available: see fulltext.].

Vecchi, A., Abete, R., Marazzato, J., Iacovoni, A., Mortara, A., De Ponti, R., et al. (2022). Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. HEART FAILURE REVIEWS, 27(1), 103-110 [10.1007/s10741-020-09991-3].

Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?

Senni M
2022

Abstract

The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ejection fraction (HFrEF) has more than halved the risk of sudden cardiac death (SCD) in this setting. However, SCD remains one of the major causes of death in this patient population. Beyond the acknowledged role of beta blockers and inhibitors of the renin-angiotensin-aldosterone system (RAAS), a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNI), proved to reduce the overall cardiovascular mortality and, more specifically, the risk of SCD in HFrEF patients. The mechanism by which ARNI may reduce the mortality connected with harmful ventricular arrhythmias is not utterly clear. A variety of direct and indirect mechanisms have been suggested, but a favorable left ventricular reverse remodeling seems to play a key role in this setting. Furthermore, the well-known protective effect of implantable cardioverter-defibrillator (ICD) has been debated in HFrEF patients with non-ischemic cardiomyopathy (NICM) arguing against the role of primary prevention ICD in this setting, particularly when ARNI therapy is considered. The purpose of this review was to provide insights into the SCD mechanisms involved in HFrEF patients together with the current role of electrical therapies and new drug agents in this setting. [Figure not available: see fulltext.].
Articolo in rivista - Articolo scientifico
Angiotensin receptor neprilysin inhibitors; Heart failure reduced ejection fraction; Implantable cardioverter-defibrillator; Sacubitril/valsartan; Sudden cardiac death; Ventricular arrhythmias;
English
2022
27
1
103
110
none
Vecchi, A., Abete, R., Marazzato, J., Iacovoni, A., Mortara, A., De Ponti, R., et al. (2022). Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. HEART FAILURE REVIEWS, 27(1), 103-110 [10.1007/s10741-020-09991-3].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372886
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
Social impact